TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03217084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MI varnish GC
Description: MI Varnish GC is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. MI Varnish also contains RECALDENT. Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: White varnish 3M
Description: White varnish 3M is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. Clinpro White Varnish contains an innovative tri-calcium phosphate.Open the unit-dose package of Varnish and dispense the entire content onto the round application guide provided with the packet. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
Study: NCT00970814

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BBCET
Description: 11 BBCET sessions

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: BBCET
Description: 11 BBCET Sessions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam XR
Description: 500mg - 2000mg Once per day 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: 500mg - 2000mg Once per day 16 weeks
Study: NCT01867957

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose GC1109
Description: 50ug/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose GC1109
Description: 100ug/dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose Placebo
Description: 0.9% Saline 0.5 mL

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: High-dose Placebo
Description: 0.9% Saline 1.0 mL
Study: NCT01990430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Intervention: The sessions included instructions in training exercises, as well as included time to speak about their fears and doubts with other patients, who were in the same situation. The intervention lasted 12 weeks (24 sessions). The training intensity was progressively increased from 65% to 85% of heart rate with control by a POLAR FT7 heart rate monitor for aerobic activities, and by 8-15 repetitions in 2-3 sets for the strength activities. Exercise intensity was prescribed using Karvonen equation.~The nutrition program consisted of three theoretical and practice classes. The first class explained the different groups of nutrients, their functions in the organism and for which group of aliments these can be obtained. The second class was a practical class about how to interpret food labels and relating measurements of food portions with recommendations for a healthy diet. Final session spoke about the ten best and the ten worst aliments, which prevent and promote cancer.
Study: NCT00119912

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A 1 Intervention arm Flex Sig
Description: Screening by flexible sigmoidoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A 2 Intervention arm Flex Sig + iFOBT
Description: In addition to Flexible Sigmoidoscopy, half of arm A (randomised 1:1) is invited to provide stool samples for FOBT
Study: NCT00730912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine
Description: Loratadine (SCH 29851) dry syrup 1% 5 mg/day for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine
Description: loratadine 10 mg tablet once daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine
Description: loratadine 10 mg tablet once daily for 4 weeks
Study: NCT00732615

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPSP558
Description: Parathyroid hormone 50, 75, or 100 mcg injectable subcutaneously daily
Study: NCT04382625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine is currently widely used for treatment of autoimmune disease including systemic lupus erythematosus and rheumatoid arthritis, and it has been used to prevent and treat malaria.
Study: NCT02360644

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Vitamin D deficient patients, in both Arms, will be administered Cholecalciferol 5,000 IU daily.
Study: NCT03586856

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal mask interface
Description: Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal prongs interface
Description: Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.
Study: NCT03637166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment at Low Altitude (470m above sea level)
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment at Low Altitude (470m above sea level)
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to High Altitude (2500m above sea level)
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to High Altitude (2500m above sea level)
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
Study: NCT00003492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT04993989

Intervention type: DRUG
Intervention: Iberogast (STW5, BAY98-7411)
Description: Survey without any intervention assigned in the study.
Study: NCT01516424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blonanserin
Description: Blonanserin tablets: 8 - 24mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone tablets: 2 - 6mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days.
Study: NCT02100059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 40 minutes.
Study: NCT00670865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic discharge summary system
Description: The customized electronic discharge summary program will be used to generate patient discharge summaries.
Study: NCT04429737

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: clam protein capsules
Description: The prediabetes patients in this arm will receive Clam protein capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clam peptide plus Chlorella capsules
Description: The prediabetes patients in this arm will receive Clam peptide plus Chlorella capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The prediabetes patients in this arm will receive Placebo with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
Study: NCT02653807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobilization with movement
Description: manual therapy intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: osteopathic mobilization
Description: manual therapy intervention
Study: NCT04446377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apilimod Dimesylate Capsule
Description: LAM-002A is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, Size 0.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose in Swedish orange, Size 0 capsules
Study: NCT01840709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Psychoanalytic brief group psychotherapy once a week for 20 consecutive weeks
Study: NCT02250755

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI T1 T2 sequences
Description: MRI
Study: NCT01890551

Intervention type: OTHER
Group type: OTHER
Intervention: Dynamic kine-mri
Description: Dynamic kinematic (KINE) magnetic resonance imaging (MRI) of the patellofemoral joint.

Intervention type: OTHER
Group type: OTHER
Intervention: Dynamic kine-mri
Description: Dynamic kinematic (KINE) magnetic resonance imaging (MRI) of the patellofemoral joint.
Study: NCT03398291

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Synchronous resection of primary pancreatic cancer and liver oligometastasis
Description: Patients undergo surgical exploration. If no extensive metastatic sites are found, the synchronous resection of primary pancreatic cancer and liver metastatic sites will be performed. Adjuvant chemotherapy was recommended, and the regimen selection is recommended to be based on the preoperative chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard chemotherapy
Description: Patients continue to receive standard chemotherapy including folinic acid, fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX), gemcitabine plus nab-paclitaxel, or gemcitabine plus S-1
Study: NCT00278655

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Autologous hematopoietic stem cell transplantation
Study: NCT02052687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 2
Description: Placebo cream 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 2
Description: Placebo cream 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 2
Description: Placebo cream 2
Study: NCT03739606

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD123/CD3 Monoclonal Antibody MGD006
Description: Given IV
Study: NCT01972906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: moxibustion
Description: apply moxibustion according to traditional Chinese medicine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Sustained Release Capsules
Description: apply Ibuprofen (H20013062), 0.3g， Bid, lasting 3 days before menstrual cycle
Study: NCT01332552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2485852 70 mg
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2485852 420 mg
Description: single dose
Study: NCT01332552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Repeat dose, once daily for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2485852 420 mg
Description: Repeat dose, twice daily for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2485852 420 mg
Description: Repeat dose, TIDfor 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2485852 630 mg
Description: Repeat dose, twice daily for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2485852 70 mg + Ritonavir 100mg
Description: single dose, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2485852 210 mg + Ritonavir 100mg
Description: single dose, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2485852 210 mg +Ritonavir 100mg
Description: single dose daily for 3 days
Study: NCT00729898

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT04224415

Intervention type: DRUG
Group type: OTHER
Intervention: C225+CPT-11
Description: Patients will receive Systemic C225+CPT-11 every 14 days:~C225 500 mg/m2 IV over 90 minutes on Day 1; Irinotecan 180 mg/m2 IV on Day 1
Study: NCT02597699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil + Lidocaïne

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil + Lidocaïne
Study: NCT03292406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Non active ingredients of CD11301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD11301 0.03%
Description: Topical Gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD11301 0.03%
Description: Topical Gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD11301 0.06%
Description: Topical Gel
Study: NCT06368999

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EEG
Description: registration of 8 minutes of EEG
Study: NCT03840096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breg Flex
Description: All subjects in the treatment group will receive quadriceps Neuro Muscular Electrical Stimulation using Breg Flex device on the affected leg to guide and monitor of knee HEP during the 6 weeks prior to surgery and 12 weeks following surgery.
Study: NCT04654390

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWP16001 Amg
Description: Tablets, Orally, Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001 Amg
Description: Tablets, Orally, Once daily
Study: NCT03803150

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRA approach
Description: A preauricular incision will be made that extends downwards in a curvilinear fashion in the cervicomastoid skin crease, though any variation in this incision will suffice. The great auricular nerve will be preserved and the flap raised in the subdermal fat plane, superficial to the superficial musculoaponeurotic layer to allow access to the masseter adjacent to the anteroinferior edge of the parotid gland, just below the parotid duct. Branches of the facial nerve will be readily identified and avoided with or without loupe magnification, on the surface of the masseter muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RT approach
Description: The incision for the retromandibular approach begins 5mm below ear lobe and continues 3 to 3.5cm inferiorly. Initial incision begins through skin and subcutaneous tissues,platysma muscle ,(SMAS), parotid capsule Dissection is continued until the only tissue remaining on the posterior border of the mandible will be the periosteum of pterygomassetric sling,then the fracture site will exposed and reduced.
Study: NCT02409043

Intervention type: OTHER
Intervention: Blood draw
Description: Blood drawn for comparison with other groups

Intervention type: OTHER
Intervention: Blood draw
Description: Blood drawn for comparison with other groups

Intervention type: OTHER
Intervention: Stroke blood draw
Description: Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, blood pressure, MRI infarct volumes, and hospital length of stay taken from the medical records. 3 month modified Rankin scale score collected by phone interview.

Intervention type: OTHER
Intervention: Stroke blood draw
Description: Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, blood pressure, MRI infarct volumes, and hospital length of stay taken from the medical records. 3 month modified Rankin scale score collected by phone interview.
Study: NCT02405000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative CT imaging
Description: Intraoperative CT scan of the upper aerodigestive tract during laryngoscopy procedure
Study: NCT00022672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab (Herceptin®)
Description: 4mg/kg iv loading dose, followed by 2mg/kg iv weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrazole (Arimidex®)
Description: 1 mg tablet taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrazole (Arimidex®)
Description: 1 mg tablet taken orally daily
Study: NCT01619319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: auditory computer games designed to improve the speed at which people react when they hear something and at which they process that information.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: computer games
Description: computer games that that consist of word puzzles
Study: NCT04517253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study: NCT04053023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330672 (linerixibat)
Description: GSK2330672 is available as a tablet with unit dose strength of 45 mg.
Study: NCT02053298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol & Dorzolamide
Description: Topical preservative-free fixed combination of timolol 0.5%+dorzolamide 2% to be applied bid for 1 month
Study: NCT01332266

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E7050
Description: E7050 given orally at 200, 300, or 400 mg once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E7050
Description: E7050 given orally at 200, 300, or 400 mg once daily.
Study: NCT03720665

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine_TMS
Description: Caffeine group: participants will receive a caffeine tablet and all electrical stimulations in a random order \[transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)\] Placebo tablet: participants will receive a placebo tablet and all electrical stimulations in a random order \[transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)\]
Study: NCT01332266

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab is given at an initial dose of 400 mg/m2 given as a 2-hour intravenous (IV) infusion on Day 1 of Cycle 1, followed by a dose of 250 mg/m2 given as a 1-hour IV infusion on Day 8, Day 15, and Day 22 of Cycle 1, and Day 1, Day 8, Day 15, and Day 22 of each subsequent cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab is given at an initial dose of 400 mg/m2 given as a 2-hour intravenous (IV) infusion on Day 1 of Cycle 1, followed by a dose of 250 mg/m2 given as a 1-hour IV infusion on Day 8, Day 15, and Day 22 of Cycle 1, and Day 1, Day 8, Day 15, and Day 22 of each subsequent cycle.
Study: NCT03720665

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine_TMS
Description: Caffeine group: participants will receive a caffeine tablet and all electrical stimulations in a random order \[transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)\] Placebo tablet: participants will receive a placebo tablet and all electrical stimulations in a random order \[transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)\]
Study: NCT01452139

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Point-of-Care Genetic Testing
Description: Point-of-Care Genetic Testing for Genetic Variants Linked to Adverse Outcomes with Clopidogrel (CYP2C19\*2 \& ABCB1 3435 TT)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Point-of-Care Genetic Testing
Description: Point-of-Care Genetic Testing for Genetic Variants Linked to Adverse Outcomes with Clopidogrel (CYP2C19\*2 \& ABCB1 3435 TT)

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Point-of-Care Genetic Testing
Description: Point-of-Care Genetic Testing for Genetic Variants Linked to Adverse Outcomes with Clopidogrel (CYP2C19\*2 \& ABCB1 3435 TT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Treatment of STEMI patients carrying at least one high risk genetic variant with prasugrel 10mg daily.
Study: NCT03112746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to Daily Occupational Performance
Description: In CO-OP Approach, therapists use mediational techniques to teach cognitive strategies - GOAL, PLAN, DO, CHECK - to improve occupational performance in goals chosen by the children in collaboration with them and their parents.